For instance, previous studies have shown that GNAS mutations can provide a help in the risk stratification and surveillance of patients with pancreatic cancer [38, 39], which may inform the diagnosis and management of PAAD. This evidence concerns the gene GNAS and familial pancreatic carcinoma.